President Jon Cartu Wrote - Clinical pathways for patients with giant cell arteritis during t... - Jonathan Cartu Family Medical Clinic & Patient Care Center
19682
post-template-default,single,single-post,postid-19682,single-format-standard,qode-quick-links-1.0,tribe-no-js,ajax_fade,page_not_loaded,,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

President Jon Cartu Wrote – Clinical pathways for patients with giant cell arteritis during t…

Clinical pathways for patients with giant cell arteritis during t...

President Jon Cartu Wrote – Clinical pathways for patients with giant cell arteritis during t…


Summary

Giant cell arteritis, a common primary systemic vasculitis affecting older people, presents acutely as a medical emergency and requires rapid specialist assessment and treatment to prevent irreversible vision loss. Disruption of the health-care system caused by the COVID-19 pandemic exposed weak points in clinical pathways for diagnosis and treatment of giant cell arteritis, but has also permitted innovative solutions. The essential roles played by all professionals, including general practitioners and surgeons, in treating these patients have become evident. Patients must also be involved in the reshaping of clinical services. As an international group of authors involved in the care of patients with giant cell arteritis, we reflect in this Viewpoint on rapid service adaptations during the first peak of COVID-19, evaluate challenges, and consider implications for the future.

Introduction

The COVID-19 pandemic has had a considerable effect on all health-care services.

  • Kutikov A
  • Weinberg DS
  • Edelman MJ
  • Horwitz EM
  • Uzzo RG
  • Fisher RI
A war on two fronts: cancer care in the time of COVID-19.